Flossbach Von Storch SE Buys New Position in Zoetis Inc. (NYSE:ZTS)

Flossbach Von Storch SE bought a new position in Zoetis Inc. (NYSE:ZTS - Free Report) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 1,775 shares of the company's stock, valued at approximately $292,000.

Other institutional investors also recently modified their holdings of the company. Brighton Jones LLC boosted its holdings in shares of Zoetis by 180.4% in the fourth quarter. Brighton Jones LLC now owns 4,629 shares of the company's stock worth $754,000 after acquiring an additional 2,978 shares during the period. Bank Pictet & Cie Europe AG grew its holdings in Zoetis by 5.4% during the 4th quarter. Bank Pictet & Cie Europe AG now owns 419,530 shares of the company's stock valued at $68,354,000 after buying an additional 21,470 shares in the last quarter. Proficio Capital Partners LLC grew its holdings in Zoetis by 61.0% during the 4th quarter. Proficio Capital Partners LLC now owns 3,053 shares of the company's stock valued at $497,000 after buying an additional 1,157 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Zoetis by 5.9% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 217,094 shares of the company's stock valued at $35,371,000 after buying an additional 12,174 shares in the last quarter. Finally, Daiwa Securities Group Inc. grew its holdings in Zoetis by 4.7% during the 4th quarter. Daiwa Securities Group Inc. now owns 75,874 shares of the company's stock valued at $12,362,000 after buying an additional 3,421 shares in the last quarter. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Zoetis Price Performance

Shares of ZTS stock traded up $0.50 during trading hours on Wednesday, hitting $158.30. 3,196,368 shares of the company's stock were exchanged, compared to its average volume of 2,580,953. The company has a market capitalization of $70.48 billion, a PE ratio of 28.42, a PEG ratio of 2.60 and a beta of 0.91. Zoetis Inc. has a 12-month low of $139.70 and a 12-month high of $200.33. The business's 50 day simple moving average is $161.27 and its 200-day simple moving average is $161.99. The company has a current ratio of 1.74, a quick ratio of 1.04 and a debt-to-equity ratio of 1.12.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported $1.48 EPS for the quarter, topping the consensus estimate of $1.40 by $0.08. The firm had revenue of $2.22 billion for the quarter, compared to the consensus estimate of $2.20 billion. Zoetis had a net margin of 27.12% and a return on equity of 55.48%. The business's revenue was up 1.4% compared to the same quarter last year. During the same period last year, the firm posted $1.38 earnings per share. On average, equities research analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Friday, July 18th will be given a $0.50 dividend. The ex-dividend date of this dividend is Friday, July 18th. This represents a $2.00 annualized dividend and a yield of 1.26%. Zoetis's payout ratio is currently 35.91%.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on ZTS shares. UBS Group reduced their target price on Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a report on Wednesday, May 7th. Stifel Nicolaus lowered Zoetis from a "buy" rating to a "hold" rating and reduced their target price for the company from $165.00 to $160.00 in a report on Wednesday, June 18th. Finally, Piper Sandler lifted their price target on Zoetis from $205.00 to $210.00 and gave the company an "overweight" rating in a research report on Monday, May 12th. Two analysts have rated the stock with a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of $212.13.

Insiders Place Their Bets

In other Zoetis news, EVP Roxanne Lagano sold 652 shares of the business's stock in a transaction that occurred on Tuesday, June 3rd. The stock was sold at an average price of $170.00, for a total value of $110,840.00. Following the completion of the sale, the executive vice president owned 15,129 shares in the company, valued at approximately $2,571,930. The trade was a 4.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 0.16% of the company's stock.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.